Tagrisso for lung cancer gets full approval in Europe

25 April 2017

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has been given full marketing authorization in Europe for Tagrisso (osimertinib) as a therapy against a particular kind of non-small cell lung cancer (NSCLC).

The decision is based on the results of a Phase III trial in which the drug showed statistically-significant improvements in survival rates compared with standard chemotherapy, in 419 patients.

The approval applies to patients with locally-advanced or metastatic ‘EGFR T790M mutation-positive’ NSCLC, a type which affects 10%-15% of NSCLC patients in the USA and Europe, and 30%-40% of patients in Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK